Sri Lanka adopts five-year national pharmaceutical policy framework

Sri Lanka's cabinet has endorsed the 2026-2030 national pharmaceutical policy, marking a significant step toward strengthening the country's medicine supply infrastructure. The policy has been developed to address critical gaps in pharmaceutical distribution and ensure that citizens have reliable access to safe, effective medications.

The framework prioritizes maintaining uninterrupted supplies of quality medicines to the general population while establishing benchmarks for pharmaceutical standards and healthcare delivery. Officials have indicated that the policy will guide the pharmaceutical sector's development over the next five years, aligning with broader public health objectives.

The initiative comes as Sri Lanka continues efforts to stabilize its healthcare system following recent economic challenges. By establishing clear strategic direction for the pharmaceutical industry, the policy aims to balance affordability, availability, and quality concerns that have affected medicine access in recent years.

Implementation of the 2026-2030 framework is expected to involve coordination between government health agencies, pharmaceutical manufacturers, and distribution networks to optimize supply chain efficiency. The policy is also designed to address regulatory standards and ensure compliance with international pharmaceutical practices.